IL15 and ductal breast carcinoma in situ: In agreement with our findings, Cohen and colleagues who used immunoassay method for the quantitation of circulating inflammatory mediators, identified zero levels of IL-15 in invasive BC patients while its level was higher in ductal carcinoma in situ (DCIS).